These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34776189)

  • 1. Effect of gentle exercises on injection site reaction after Covid-19 vaccination. A case report.
    Kalia V
    J Bodyw Mov Ther; 2021 Oct; 28():527-529. PubMed ID: 34776189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Traditional Chinese medicine auricular point acupressure for the relief of pain, fatigue, and gastrointestinal adverse reactions after the injection of novel coronavirus-19 vaccines: a structured summary of a study protocol for a multicentre, three-arm, single-blind, prospective randomized controlled trial.
    Fu Q; Xie H; Zhou L; Li X; Liu Y; Liu M; Wang C; Wang X; Wang Z; Tang J; Xiao H; Xiao Z; Zhou J; Feng C; Wang L; Ao Z; Chen X; Su C; Wu X; Zhao M; Hu S; Lin H; Huang J; Xu G; Zhang Q; Jiang L
    Trials; 2021 Feb; 22(1):162. PubMed ID: 33632286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis.
    Guo Y; Cao XS; Yang HT; Zhou MG; Yu B
    J Glob Health; 2023 Feb; 13():06008. PubMed ID: 36757823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaphylaxis is a rare reaction in COVID-19 vaccination.
    Bellomo RG; Gallenga CE; Caraffa A; Tetè G; Ronconi G; Conti P
    J Biol Regul Homeost Agents; 2021; 35(3):839-842. PubMed ID: 34105336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
    Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
    Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration (SIRVA).
    Cantarelli Rodrigues T; Hidalgo PF; Skaf AY; Serfaty A
    Skeletal Radiol; 2021 Nov; 50(11):2293-2297. PubMed ID: 33944967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases.
    Petruzzi M; Galleggiante S; Messina S; Della Vella F
    BMC Oral Health; 2022 Mar; 22(1):90. PubMed ID: 35331228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
    J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
    Català A; Muñoz-Santos C; Galván-Casas C; Roncero Riesco M; Revilla Nebreda D; Solá-Truyols A; Giavedoni P; Llamas-Velasco M; González-Cruz C; Cubiró X; Ruíz-Villaverde R; Gómez-Armayones S; Gil Mateo MP; Pesqué D; Marcantonio O; Fernández-Nieto D; Romaní J; Iglesias Pena N; Carnero Gonzalez L; Tercedor-Sanchez J; Carretero G; Masat-Ticó T; Rodríguez-Jiménez P; Gimenez-Arnau AM; Utrera-Busquets M; Vargas Laguna E; Angulo Menéndez AG; San Juan Lasser E; Iglesias-Sancho M; Alonso Naranjo L; Hiltun I; Cutillas Marco E; Polimon Olabarrieta I; Marinero Escobedo S; García-Navarro X; Calderón Gutiérrez MJ; Baeza-Hernández G; Bou Camps L; Toledo-Pastrana T; Guilabert A
    Br J Dermatol; 2022 Jan; 186(1):142-152. PubMed ID: 34254291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous adverse reactions of COVID-19 vaccines: A systematic review.
    Qaderi K; Golezar MH; Mardani A; Mallah MA; Moradi B; Kavoussi H; Shamsabadi A; Golezar S
    Dermatol Ther; 2022 May; 35(5):e15391. PubMed ID: 35194894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site.
    Myles IA; Vinciguerra JS; Premus RT
    Vaccine; 2021 Jul; 39(32):4404-4406. PubMed ID: 34217573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
    Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
    Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status.
    Cao Z; Zhang C; Zhao S; Sheng Z; Xiang X; Li R; Qian Z; Wang Y; Chen B; Li Z; Liu Y; An B; Zhou H; Cai W; Wang H; Gui H; Xin H; Xie Q
    Infect Dis Poverty; 2022 May; 11(1):56. PubMed ID: 35578350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.